Lineage Cell Therapeutics (LCTX) FCF Margin (2010 - 2026)

Lineage Cell Therapeutics' FCF Margin history runs 17 years deep, the most recent figure standing at 471.48% for Q1 2026.

• On a quarterly basis, FCF Margin fell 13972.0% year-over-year to 471.48% in Q1 2026; TTM through Mar 2026 was 152.86%, a 8591.0% increase from a year earlier, with the FY2025 full-year figure at 133.56%, up 11549.0% from the prior year.
• FCF Margin fell to 471.48% in Q1 2026 per LCTX's latest filing, from 81.34% in the prior quarter.
• Across five years, FCF Margin topped out at 417.38% in Q1 2022 and bottomed at 477.58% in Q1 2023.
• The 5-year median for FCF Margin is 240.59% (2024), against an average of 240.06%.
• Across the five-year window, FCF Margin surged 231891 bps in 2022 and slumped 89495 bps in 2023, its largest moves.
• Year by year, FCF Margin stood at 412.64% in 2022, then advanced by 29 bps to 292.62% in 2023, then advanced by 18 bps to 240.59% in 2024, then jumped by 66 bps to 81.34% in 2025, then tumbled by 480 bps to 471.48% in 2026.
• Per Business Quant, the three latest LCTX FCF Margin figures stand at 471.48% (Q1 2026), 81.34% (Q4 2025), and 95.9% (Q3 2025).